True reactivation versus transient viremia: a retrospective analysis of HBV reactivation in resolved infection
Tadashi Inuzuka, Atsushi Takai, Masayuki Ueno, Masako Mishima, Haruhiko Takeda, Ken Takahashi, Takahisa Kayahara, Hiroyuki Takabatake, Hirokazu Mouri, Hiroshi Seno · 2026
Read True reactivation versus transient viremia: a retrospective analysis of HBV reactivation in resolved infection by Tadashi Inuzuka, Atsushi Takai, Masayuki Ueno, Masako Mishima, Haruhiko Takeda, Ken Takahashi, Takahisa Kayahara, Hiroyuki Takabatake, Hirokazu Mouri, Hiroshi Seno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13470127.txt.
Description
Tadashi Inuzuka and colleagues separated true hepatitis B reactivation in 2026 from fleeting viral blips in patients with resolved infection on immune suppression. Low-level viral DNA return carries unclear meaning, yet overtreatment wastes drugs and undertreatment risks liver injury. Sixty-nine patients with viral reappearance were reviewed, with 38 initially watched without immediate antivirals.
Of the watched group, 7 progressed to true reactivation at 3.3 log units or more, 18 cleared spontaneously, and 13 started antivirals before either outcome. Every patient starting at 2.0 log units or more progressed, against only 2 of 20 below that line, and blood cancers raised risk sharply. Initial load plus disease type may thus guide watchful waiting versus early treatment.
Catalog record
| CREATOR | Tadashi Inuzuka, Atsushi Takai, Masayuki Ueno, Masako Mishima, Haruhiko Takeda, Ken Takahashi, Takahisa Kayahara, Hiroyuki Takabatake, Hirokazu Mouri, Hiroshi Seno |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |